Dr. Modest on Study of Surgical Intervention in CRC

Dominik P. Modest, MD
Published: Thursday, Jul 06, 2017



Dominik P. Modest, MD, University of Munich, discusses an evaluation of resection in patients with metastatic colorectal cancer (mCRC).

In a central evaluation for surgical treatment options in the FIRE-3 study results, a panel of 8 surgeons and 3 medical oncologists served as reviewers of 448 patients, defining resectability as at least 50% of the reviewers recommending surgical intervention.

Findings showed that roughly 20% of the population would have been a candidate for surgical intervention and at best response, it was a little more than 50%, says Modest.
 


Dominik P. Modest, MD, University of Munich, discusses an evaluation of resection in patients with metastatic colorectal cancer (mCRC).

In a central evaluation for surgical treatment options in the FIRE-3 study results, a panel of 8 surgeons and 3 medical oncologists served as reviewers of 448 patients, defining resectability as at least 50% of the reviewers recommending surgical intervention.

Findings showed that roughly 20% of the population would have been a candidate for surgical intervention and at best response, it was a little more than 50%, says Modest.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x